465 results on '"Lietman TM"'
Search Results
2. Short-term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection (vol 8, 535, 2015)
- Author
-
Porco, Travis, Lietman, Thomas, Liu, F, Porco, TC, Amza, A, Kadri, B, Nassirou, B, West, SK, Bailey, RL, Keenan, JD, and Lietman, TM
- Published
- 2016
3. Correction: Evaluating Subcriticality during the Ebola Epidemic in West Africa.
- Author
-
Lietman, Thomas, Enanoria, WTA, Worden, L, Liu, F, Gao, D, Ackley, S, Scott, J, Deiner, M, Mwebaze, E, Ip, W, and Lietman, TM
- Abstract
[This corrects the article DOI: 10.1371/journal.pone.0140651.].
- Published
- 2016
4. Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) Cornea and external eye diseases
- Author
-
Acharya, Nisha, Lietman, Thomas, Sy, A, O'Brien, KS, Liu, MP, Cuddapah, PA, Acharya, NR, Lietman, TM, and Rose-Nussbaumer, J
- Abstract
© 2015 Sy et al.Background: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common tre
- Published
- 2015
5. Correction: The Distribution of Ocular Chlamydia Prevalence across Tanzanian Communities Where Trachoma Is Declining.
- Author
-
Lietman, Thomas, Keenan, Jeremy, Porco, Travis, Rahman, SA, West, SK, Mkocha, H, Munoz, B, Porco, TC, Keenan, JD, and Lietman, TM
- Published
- 2015
6. Microbial keratitis: a community eye health approach.
- Author
-
Keenan, Jeremy, Lietman, Thomas, O'Brien, KS, Lietman, TM, Keenan, JD, and Whitcher, JP
- Published
- 2015
7. The efficacy of oral azithromycin in clearing ocular chlamydia: Mathematical modeling from a community-randomized trachoma trial
- Author
-
Porco, Travis, Lietman, Thomas, Liu, F, Porco, TC, Mkocha, HA, Muñoz, B, Ray, KJ, Bailey, RL, Lietman, TM, and West, SK
- Abstract
Mass oral azithromycin distributions have dramatically reduced the prevalence of the ocular strains of chlamydia that cause trachoma. Assessing efficacy of the antibiotic in an individual is important in planning trachoma elimination. However, the efficacy
- Published
- 2014
8. Antibiotic use as a tragedy of the commons: A cross-sectional survey
- Author
-
Lietman, Thomas, O'Brien, KS, Blumberg, S, Enanoria, WTA, Ackley, S, Sippl-Swezey, N, and Lietman, TM
- Abstract
Background. Many believe antibiotic use results in a tragedy of the commons, since overuse may lead to antibiotic resistance and limiting use would benefit society. In contrast, mass antibiotic treatment programs are thought to result in community-wide ben
- Published
- 2014
9. Improvement in corneal scarring following bacterial keratitis
- Author
-
McClintic, SM, Srinivasan, M, Mascarenhas, J, Greninger, DA, Acharya, NR, Lietman, TM, and Keenan, JD
- Subjects
Biomedical and Clinical Sciences ,Ophthalmology and Optometry ,Clinical Trials and Supportive Activities ,Clinical Research ,Physical Injury - Accidents and Adverse Effects ,Eye Disease and Disorders of Vision ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Eye ,Adult ,Aged ,Aza Compounds ,Cicatrix ,Corneal Ulcer ,Eye Infections ,Bacterial ,Female ,Fluoroquinolones ,Humans ,Male ,Middle Aged ,Moxifloxacin ,Ophthalmic Solutions ,Pneumococcal Infections ,Prednisolone ,Pseudomonas Infections ,Quinolines ,Vision Disorders ,Visual Acuity ,corneal ulcer ,corneal scar ,SCUT ,Clinical Sciences ,Immunology ,Opthalmology and Optometry ,Ophthalmology & Optometry ,Ophthalmology and optometry - Abstract
AimBacterial keratitis results in corneal scarring and subsequent visual impairment. The long-term evolution of corneal scars has not been well described. In this case series, we identified patients who had improvement in corneal scarring and visual acuity from a clinical trial for bacterial keratitis.MethodsWe searched the records of the Steroids for Corneal Ulcers Trial (SCUT) for patients who had improvement in vision between the 3-month and 12-month visits and reviewed their clinical photographs.ResultsOf the 500 patients enrolled in SCUT, five patients with large central corneal scars due to bacterial keratitis are presented. All experienced improvement in rigid contact lens-corrected visual acuity from months 3 to 12. All patients also had marked improvement in corneal opacity during the same time period. None of the patients opted to have penetrating keratoplasty.ConclusionsCorneal scars may continue to improve even many months after a bacterial corneal ulcer has healed. The corneal remodeling can be accompanied by considerable improvement in visual acuity, such that corneal transplantation may not be necessary.
- Published
- 2013
10. Elimination and Eradication of Neglected Tropical Diseases with Mass Drug Administrations: A Survey of Experts
- Author
-
Keenan, Jeremy, Porco, Travis, Lietman, Thomas, Keenan, JD, Hotez, PJ, Amza, A, Stoller, NE, Gaynor, BD, Porco, TC, and Lietman, TM
- Abstract
Background:Lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths, and trachoma are the five most prevalent neglected tropical diseases in the world, and each is frequently treated with mass drug administrations. We performed a s
- Published
- 2013
11. Assessment of Transmission in Trachoma Programs over Time Suggests No Short-Term Loss of Immunity
- Author
-
Porco, Travis, Lietman, Thomas, Liu, F, Porco, TC, Ray, KJ, Bailey, RL, Mkocha, H, Muñoz, B, Quinn, TC, Lietman, TM, and West, SK
- Abstract
Trachoma programs have dramatically reduced the prevalence of the ocular chlamydia that cause the disease. Some have hypothesized that immunity to the infection may be reduced because of program success in reducing the incidence of infection, and transmiss
- Published
- 2013
12. Association between Ocular Bacterial Carriage and Follicular Trachoma Following Mass Azithromycin Distribution in The Gambia
- Author
-
Lietman, Thomas, Burr, SE, Hart, JD, Edwards, T, Baldeh, I, Bojang, E, Harding-Esch, EM, Holland, MJ, Lietman, TM, West, SK, and Mabey, DCW
- Abstract
Background:Trachoma, caused by ocular Chlamydia trachomatis infection, is the leading infectious cause of blindess, but its prevalence is now falling in many countries. As the prevalence falls, an increasing proportion of individuals with clinical signs of
- Published
- 2013
13. When Does Overuse of Antibiotics Become a Tragedy of the Commons?
- Author
-
Porco, Travis, Lietman, Thomas, Porco, TC, Gao, D, Scott, JC, Shim, E, Enanoria, WT, Galvani, AP, and Lietman, TM
- Abstract
Background: Over-prescribing of antibiotics is considered to result in increased morbidity and mortality from drug-resistant organisms. A resulting common wisdom is that it would be better for society if physicians would restrain their prescription of anti
- Published
- 2012
14. Application of smartphone cameras for detecting clinically active trachoma
- Author
-
Lietman, Thomas, Keenan, Jeremy, Bhosai, SJ, Amza, A, Beido, N, Bailey, RL, Keenan, JD, Gaynor, BD, and Lietman, TM
- Published
- 2012
15. Predictors of outcome in fungal keratitis.
- Author
-
Prajna, N Venkatesh, Krishnan, T, Mascarenhas, J, Srinivasan, M, Oldenburg, CE, Toutain-Kidd, CM, Sy, A, McLeod, SD, Zegans, ME, Acharya, NR, Lietman, TM, and Porco, TC
- Subjects
Humans ,Corneal Ulcer ,Eye Infections ,Fungal ,Natamycin ,Triazoles ,Pyrimidines ,Ophthalmic Solutions ,Antifungal Agents ,Prognosis ,Debridement ,Administration ,Topical ,Risk Factors ,Prospective Studies ,Double-Blind Method ,Visual Acuity ,Time Factors ,Female ,Male ,Corneal Perforation ,Re-Epithelialization ,Voriconazole ,Outcome and Process Assessment ,Health Care ,Eye Disease and Disorders of Vision ,Clinical Research ,Eye ,fungus ,keratitis ,risk factors ,Clinical Sciences ,Immunology ,Opthalmology and Optometry ,Ophthalmology & Optometry - Abstract
PurposeTo analyse predictors of clinical outcome in fungal keratitis.MethodsData was collected during a prospective, randomized, controlled, double-masked clinical trial of treatment for fungal keratitis. Clinical features at presentation and demographics were collected at the enrollment visit for all patients. Pre-specified clinical outcomes included 3-month visual acuity and infiltrate/scar size, time to re-epithelialization, and corneal perforation. A separate multivariable model with each outcome as the dependent variable included all predictor variables.ResultsPredictors for worse 3-month visual acuity include older age (P=0.024), worse presentation visual acuity (P
- Published
- 2012
16. Vision-related quality-of-life outcomes in the Mycotic Ulcer Treatment Trial I: A randomized clinical trial
- Author
-
Rose-Nussbaumer, J, Prajna, NV, Krishnan, KT, Mascarenhas, J, Rajaraman, R, Srinivasan, M, Raghavan, A, Oldenburg, CE, O'Brien, KS, Ray, KJ, McLeod, SD, Porco, TC, Lietman, TM, Acharya, NR, Keenan, JD, Lalitha, P, Karpagam, R, Rajkumar, M, Sumithra, SR, Sundar, C, Manikandan, P, Shivananda, N, Whitcher, JP, Lee, S, Cevallos, V, Shapiro, BL, Hong, KC, Fisher, M, Aldave, A, Everett, D, Glover, J, Kannan, KA, Kymes, S, Schwab, I, Everett, DF, Zegans, ME, and Kidd, CM
- Abstract
IMPORTANCE: Given the limitations in health care resources, quality-of-life measures for interventions have gained importance. OBJECTIVE: To determine whether vision-related quality-of-life outcomes were different between the natamycin and voriconazole treatment arms in the Mycotic Ulcer Treatment Trial I, as measured by an Indian Vision Function Questionnaire. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis (performed October 11-25, 2014) of a double-masked, multicenter, randomized, active comparator-controlled, clinical trial at multiple locations of the Aravind Eye Care System in South India that enrolled patients with culture- or smear-positive filamentous fungal corneal ulcers who had a baseline visual acuity of 20/40 to 20/400 (logMAR of 0.3-1.3). INTERVENTIONS: Study participants were randomly assigned to topical voriconazole, 1%, or topical natamycin, 5%. MAIN OUTCOMES AND MEASURES: Subscale score on the Indian Vision Function Questionnaire from each of the 4 subscales (mobility, activity limitation, psychosocial impact, and visual function) at 3 months. RESULTS: A total of 323 patients were enrolled in the trial, and 292 (90.4%) completed the Indian Vision Function Questionnaire at 3 months. The majority of study participants had subscale scores consistent with excellent function. After adjusting for baseline visual acuity and organism, we found that study participants in the natamycin-treated group scored, on average, 4.3 points (95%CI, 0.1-8.5) higher than study participants in the voriconazoletreated group (P =.046). In subgroup analyses looking at ulcers caused by Fusarium species and adjusting for baseline best spectacle-corrected visual acuity, the natamycin-treated group scored 8.4 points (95%CI, 1.9-14.9) higher than the voriconazole-treated group (P =.01). Differences in quality of life were not detected for patients with Aspergillus or other non-Fusarium species as the causative organism (1.5 points [95%CI, -3.9 to 6.9]; P =.52). CONCLUSIONS AND RELEVANCE: We found evidence of improvement in vision-related quality of life among patients with fungal ulcers who were randomly assigned to natamycin compared with those randomly assigned to voriconazole, and especially among patients with Fusarium species as the causative organism. Incorporation of quality-of-life measures in clinical trials is important to fully evaluate the effect of the studied interventions.
- Published
- 2015
17. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT)
- Author
-
Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR, and Steroids for Corneal Ulcers Trial Group
- Published
- 2012
18. The steroids for corneal ulcers trial: study design and baseline characteristics.
- Author
-
Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR, and Steroids for Corneal Ulcers Trial Group
- Published
- 2012
19. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
- Author
-
Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P, Gaynor BD, Lietman TM, Porco, Travis C, Gebre, Teshome, Ayele, Berhan, House, Jenafir, Keenan, Jeremy, Zhou, Zhaoxia, Hong, Kevin Cyrus, and Stoller, Nicole
- Abstract
Context: Mass oral azithromycin distribution to affected communities is a cornerstone of the World Health Organization's trachoma elimination program. Antibiotics are provided to target the ocular strains of chlamydia that cause trachoma, but may also be efficacious against respiratory disease, diarrhea, and malaria--frequent causes of childhood mortality in trachoma-endemic areas.Objective: To compare mortality rates of participants aged 1 to 9 years in treated communities with those in untreated communities.Design, Setting, and Participants: We conducted a cluster-randomized clinical trial of mass azithromycin administration for trachoma control. Forty-eight communities (known as subkebeles) were randomized into 1 of 3 treatment schedules (annual treatment of all residents [15,902 participants], biannual treatment of all residents [17,288 participants], or quarterly treatment of children only [14,716 participants]) or into 1 group for which treatment was delayed by 1 year (control, 18,498 participants). Twelve subkebeles were randomized to each of the 4 schedules with all children in each of the 3 communities being eligible for treatment. The trial was conducted in a field setting in rural Ethiopia, May 2006 to May 2007.Interventions: A single dose of oral azithromycin (adults, 1 g; children, 20 mg/kg) was administered for treatment of ocular Chlamydia trachomatis infection. Antibiotic coverage levels for children aged 1 to 9 years exceeded 80% at all visits.Main Outcome Measure: The main outcome measure was the community-specific mortality risk for children aged 1 to 9 years over the course of 1 year. Mortality was measured by enumerative census at baseline and again after 1 year. Comparison of the risk of mortality was a prespecified outcome for the clinical trial.Results: The odds ratio for childhood mortality in the intervention communities was 0.51 (95% confidence interval, 0.29-0.90; P = .02; clustered logistic regression) compared with the control group. In the treated communities, the estimated overall mortality rate during this period for children aged 1 to 9 years in the untreated group was 8.3 per 1000 person-years (95% confidence interval, 5.3-13.1), while among the treated communities, the estimated overall mortality rate was 4.1 per 1000 person-years (95% confidence interval, 3.0-5.7) for children aged 1 to 9 years.Conclusion: In a trachoma-endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children.Trial Registration: clinicaltrials.gov Identifier: NCT00322972. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
20. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma.
- Author
-
Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, Cevallos V, Zhou Z, Maxey K, Lee DC, Shapiro BL, Srinivasan M, Porco T, Whitcher JP, Gaynor BD, and Lietman TM
- Published
- 2006
- Full Text
- View/download PDF
21. Single-dose azithromycin for trachoma.
- Author
-
Lietman TM, Gaynor B, Porco T, Solomon AW, Foster A, and Mabey DCW
- Published
- 2005
22. Trachoma research: it takes more than a village.
- Author
-
Lietman TM, Neuwelt MD, Gandhi NG, Dalmon CA, and Benitah N
- Published
- 2006
- Full Text
- View/download PDF
23. Blindness: a global priority for the twenty-first century.
- Author
-
Cunningham ET Jr., Lietman TM, and Whitcher JP
- Published
- 2001
24. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.
- Author
-
Gebre T, Ayele B, Zerihun M, Genet A, Stoller NE, Zhou Z, House JI, Yu SN, Ray KJ, Emerson PM, Keenan JD, Porco TC, Lietman TM, Gaynor BD, Gebre, Teshome, Ayele, Berhan, Zerihun, Mulat, Genet, Asrat, Stoller, Nicole E, and Zhou, Zhaoxia
- Abstract
Background: In trachoma control programmes, azithromycin is distributed to treat the strains of chlamydia that cause ocular disease. We aimed to compare the effect of annual versus twice-yearly distribution of azithromycin on infection with these strains.Methods: We did a cluster-randomised trial in 24 subdistricts in northern Ethiopia, which we randomly assigned to receive annual or twice-yearly treatment for all residents of all ages. Random assignment was done with the RANDOM and SORT functions of Microsoft Excel. All individuals were offered their assigned treatment of a single, directly observed, oral dose of azithromycin. A 6 week course of topical 1% tetracycline ointment, applied twice daily to both eyes but not directly observed, was offered as an alternative to azithromycin in patients younger than 12 months, and in patients with self-reported pregnancy, with allergy, or who refused azithromycin. Our primary, prespecified outcome was the prevalence of ocular chlamydial infection in a random sample of children aged 0-9 years at baseline and every 6 months for a total of 42 months within sentinel villages. Our analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00322972.Findings: Antibiotic coverage of children aged 1-9 years was greater than 80% (range 80·9 to 93·0) at all study visits. In the groups treated annually, the prevalence of infection in children aged 0-9 years was reduced from a mean 41·9% (95% CI 31·5 to 52·2) at baseline to 1·9% (0·3 to 3·5) at 42 months. In the groups treated twice yearly, the prevalence of infection was reduced from a mean 38·3% (29·0 to 47·6) at baseline to 3·2 % (0·0 to 6·5) at 42 months. The prevalence of ocular chlamydial infection in children aged 0-9 years in groups treated annually was not different from that of the groups treated twice yearly at 18, 30, and 42 months (pooled regression p>0·99, 95 % CI -0·06 to 0·06). The mean elimination time in the twice-yearly treatment group was 7·5 months earlier (2·3 to 17·3) than that of the annual group (p=0·10, Cox proportional hazards model).Interpretation: After 42 months of treatment, the prevalence of ocular infection with chlamydia was similar in the groups treated annually and twice yearly. However, elimination of infection might have been more rapid in the groups of villages that received treatment twice yearly.Funding: National Institutes of Health (NEI U10 EY016214). [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
25. Coxsackievirus A24 causing acute conjunctivitis in a 2023 outbreak in Vietnam.
- Author
-
Tran H, Ha T, Hoang L, Tran Y, Ruder K, Zhong L, Chen C, Liu Y, Yu D, Abraham T, Hinterwirth A, Deiner M, Porco TC, Lietman TM, Doan T, and Seitzman GD
- Subjects
- Humans, Vietnam epidemiology, Male, Female, Adult, Middle Aged, Young Adult, Child, Adolescent, Child, Preschool, Conjunctivitis, Viral epidemiology, Conjunctivitis, Viral virology, Conjunctivitis, Acute Hemorrhagic epidemiology, Conjunctivitis, Acute Hemorrhagic virology, Disease Outbreaks, Coxsackievirus Infections epidemiology, Coxsackievirus Infections virology, Phylogeny
- Abstract
Objectives: To determine the associated pathogen during the 2023 conjunctivitis outbreak in Vietnam METHODS: RNA-sequencing was used to identify pathogens before and during the outbreak., Results: 24 patients with infectious conjunctivitis between March and October 2023 from Hai Yen Vision Institute in Vietnam were swabbed. Coxsackievirus A24v was the most common pathogen identified. Phylogenetic analysis of these strains demonstrates similarities to the Coxsackievirus identified in the 2022 India outbreak. Human adenovirus D was also circulating. Ocular findings of tearing, purulence, and itching were common in this outbreak., Conclusions: Multiple viruses can co-circulate during conjunctivitis outbreaks. Hemorrhagic conjunctivitis, commonly associated with coxsackievirus conjunctivitis, was not a common clinical sign in this outbreak. Repeat genetic surveillance, with the notable inclusion of RNA virus detection strategies, is important for outbreak detection., Competing Interests: Declarations of competing interest The authors have no relevant financial or non-financial competing interests to report., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Steroids and Cross-Linking for Ulcer Treatment Trial II: Baseline Characteristics.
- Author
-
Prajna VN, Radhakrishnan N, Lalitha PS, Rajaraman R, Christy J, Venugopal A, Abdelrahman S, Srinivasan A, Varnado N, Arnold B, Amescua G, Lietman TM, and Rose-Nussbaumer JR
- Abstract
Purpose: The Steroids and Cross-linking for Ulcer Treatment Trial is an NIH-funded international, randomized, double-masked, sham and placebo-controlled clinical trial to determine the benefit of adjunctive corneal cross-linking with riboflavin and/or topical difluprednate in addition to topical antibiotic drops for treatment of smear-positive bacterial ulcers. The purpose of this study was to explore the baseline characteristics for infection of patients enrolled, and the ocular comorbidities of patients screened for inclusion., Methods: Of the 2005 patients with smear-positive bacterial ulcers screened, 280 patients were enrolled. Descriptive statistics were used to summarize and characterize the data., Results: Eligible patients in India had baseline factors associated with agricultural work (N = 132; 47%) and manual labor (N = 54; 19%), whereas patients in the United States were associated with contact lens wear (N = 11; 69%) (P <0.001). Nearly, 10% of patients with unilateral infectious keratitis are at risk of bilateral blindness because of preexisting visual disability in their other eye and thus ineligible for inclusion. India had higher rates of exclusionary factors for blindness in the other eye such as cataract (N = 48; 27%) and glaucoma (N = 24; 13) compared with the United States (N = 0; 0%) (P <0.001)., Conclusions: While corneal ulceration is an important cause of disability in technologically advanced countries, it occurs more frequently in low and middle-income countries, and the implications on these populations should be considered. These baseline factors can be evaluated to address such health care disparities., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial.
- Author
-
O'Brien KS, Arzika AM, Amza A, Maliki R, Aichatou B, Bello IM, Beidi D, Galo N, Harouna N, Karamba AM, Mahamadou S, Abarchi M, Ibrahim A, Lebas E, Peterson B, Liu Z, Le V, Colby E, Doan T, Keenan JD, Oldenburg CE, Porco TC, Arnold BF, and Lietman TM
- Subjects
- Child, Preschool, Female, Humans, Infant, Male, Chemoprevention adverse effects, Chemoprevention statistics & numerical data, Drug Resistance, Bacterial, Niger epidemiology, Rural Population statistics & numerical data, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Azithromycin administration & dosage, Azithromycin adverse effects, Bacterial Infections mortality, Bacterial Infections prevention & control, Child Mortality, Infant Mortality, Mass Drug Administration adverse effects, Mass Drug Administration statistics & numerical data
- Abstract
Background: Twice-yearly mass distribution of azithromycin to children is a promising intervention to reduce childhood mortality in sub-Saharan Africa. The World Health Organization recommended restricting distribution to infants 1 to 11 months of age to mitigate antimicrobial resistance, although this more limited treatment had not yet been tested., Methods: We randomly assigned rural communities in Niger to four twice-yearly distributions of azithromycin for children 1 to 59 months of age (child azithromycin group), four twice-yearly distributions of azithromycin for infants 1 to 11 months of age and placebo for children 12 to 59 months of age (infant azithromycin group), or placebo for children 1 to 59 months of age. Census workers who were not aware of the group assignments monitored mortality twice yearly over the course of 2 years. We assessed three primary community-level mortality outcomes (deaths per 1000 person-years), each examining a different age group and pairwise group comparison., Results: A total of 1273 communities were randomly assigned to the child azithromycin group (1229 were included in the analysis), 773 to the infant azithromycin group (751 included in the analysis), and 954 to the placebo group (929 included in the analysis). Among 382,586 children, 419,440 person-years and 5503 deaths were recorded. Lower mortality among children 1 to 59 months of age was observed in the child azithromycin group (11.9 deaths per 1000 person-years; 95% confidence interval [CI], 11.3 to 12.6) than in the placebo group (13.9 deaths per 1000 person-years; 95% CI, 13.0 to 14.8) (representing 14% lower mortality with azithromycin; 95% CI, 7 to 22; P<0.001). Mortality among infants 1 to 11 months of age was not significantly lower in the infant azithromycin group (22.3 deaths per 1000 person-years; 95% CI, 20.0 to 24.7) than in the placebo group (23.9 deaths per 1000 person-years; 95% CI, 21.6 to 26.2) (representing 6% lower mortality with azithromycin; 95% CI, -8 to 19). Five serious adverse events were reported: three in the placebo group, one in the infant azithromycin group, and one in the child azithromycin group., Conclusions: Azithromycin distributions to children 1 to 59 months of age significantly reduced mortality and was more effective than treatment of infants 1 to 11 months of age. Antimicrobial resistance must be monitored. (Funded by the Bill and Melinda Gates Foundation; AVENIR ClinicalTrials.gov number, NCT04224987.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
28. Association of weather variables with pathogens contributing to conjunctivitis worldwide.
- Author
-
Yan D, Prajna NV, Lalitha P, Sansanayudh W, Satitpitakul V, Laovirojjanakul W, Chaudhary M, Bountogo M, Sie A, Coulibaly B, Amza A, Nassirou B, Almou I, Tran H, Tran Y, Tsui E, Onclinx T, Sella R, Goren L, McClean E, Tham V, Chen C, Ruder K, Zhong L, Liu Y, Yu D, Abraham T, Lebas E, Arnold BF, McLeod SD, Deiner MS, Porco TC, Seitzman GD, Lietman TM, Shantha J, Hinterwirth A, and Doan T
- Abstract
Purpose: To identify weather variables associated with pathogens contributing to infectious conjunctivitis globally., Methods: Sample collection and pathogen identification from patients with acute infectious conjunctivitis was performed from 2017 to 2023. We linked pathogens identified from 13 sites across 8 countries with publicly available weather data by geographic coordinates. Mixed effects logistic regression analysis was performed to estimate the associations between temperature, precipitation, and relative humidity exposures, and the prevalence of infection types (RNA virus, DNA virus, bacteria, and fungus)., Results: 498 cases from the United States, India, Nepal, Thailand, Burkina Faso, Niger, Vietnam, and Israel were included in the analysis. 8-day average precipitation (mm) was associated with increased odds of RNA virus infection (odds ratio (OR)=1.47, 95% confidence interval (CI): 1.12 to 1.93, P=0.01) and decreased odds of DNA infection (OR=0.62, 95% CI: 0.46 to 0.82, P<0.001). Relative humidity (%) was associated with increased odds of RNA virus infections (OR=2.64, 95% CI: 1.51 to 4.61, P<0.001), and fungal infections (OR=2.35, 95% CI: 1.19 to 4.66, P=0.01), but decreased odds of DNA virus (OR=0.58, 95%CI: 0.37 to 0.90, P=0.02) and bacterial infections (OR=0.42, 95% CI: 0.25 to 0.71, P<0.001). Temperature (°C) was not associated with ocular infections for any pathogen type., Conclusions: This study suggests that weather factors affect pathogens differently. Particularly, humidity and precipitation were predictors for pathogens contributing to conjunctivitis worldwide. Additional work is needed to clarify the effects of shifts in weather and environmental factors on ocular infectious diseases., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
29. Seroreversion to Chlamydia trachomatis Pgp3 Antigen Among Children in a Hyperendemic Region of Amhara, Ethiopia.
- Author
-
Tedijanto C, Aragie S, Gwyn S, Wittberg DM, Zeru T, Tadesse Z, Chernet A, Thompson IJB, Nash SD, Lietman TM, Martin DL, Keenan JD, and Arnold BF
- Subjects
- Humans, Ethiopia epidemiology, Child, Preschool, Female, Male, Infant, Longitudinal Studies, Child, Endemic Diseases, Chlamydia trachomatis immunology, Antigens, Bacterial immunology, Immunoglobulin G blood, Immunoglobulin G immunology, Trachoma epidemiology, Trachoma microbiology, Trachoma immunology, Antibodies, Bacterial blood, Antibodies, Bacterial immunology, Bacterial Proteins immunology
- Abstract
Monitoring trachoma transmission with antibody data requires characterization of decay in IgG to Chlamydia trachomatis antigens. In a 3-year longitudinal cohort in a high-transmission setting, we estimated a median IgG half-life of 3 years and a seroreversion rate of 2.5 per 100 person-years (95% confidence interval, 1.6-3.5). Clinical Trials Registration NCT02754583., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
30. Biomarker Detection and Validation for Corneal Involvement in Patients With Acute Infectious Conjunctivitis.
- Author
-
Seitzman GD, Prajna L, Prajna NV, Sansanayudh W, Satitpitakul V, Laovirojjanakul W, Chen C, Zhong L, Ouimette K, Redd T, Deiner MC, Porco TC, McLeod SD, Lietman TM, Hinterwirth A, and Doan T
- Abstract
Importance: Infectious conjunctivitis can lead to corneal involvement and result in ocular morbidity. The identification of biomarkers associated with corneal involvement has the potential to improve patient care., Objective: To identify biomarkers in patients with acute infectious conjunctivitis., Design, Setting, and Participants: This cross-sectional study took place from December 2016 to March 2024. Analyses were performed in 3 phases. First, logistic regression and machine learning algorithms were used to predict the probability of demonstrating corneal involvement in patients with presumed infectious conjunctivitis. Second, quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to confirm the most important biomarker gene identified by the algorithm. Third, the biomarker gene was validated in prospectively collected conjunctival samples of adult patients from 3 outpatient centers in Thailand and 1 in India. Patients with signs and symptoms of infectious conjunctivitis and onset within less than 14 days were eligible. Exclusion criteria were the inability to consent, presumed toxicity, or allergic conjunctivitis., Exposures: Acute infectious conjunctivitis., Main Outcomes and Measures: The identification and validation of ocular surface gene expression associated with corneal findings on slitlamp examination., Results: Thirteen genes exhibited a 1.5-log2 fold change in expression in patients with corneal involvement compared to patients without corneal involvement. Using the 13 genes to train and cross validate, logistic regression produced the highest mean area under the receiver operating characteristic curve (AUROC; 0.85; 95% CI, 0.84-0.86) for corneal involvement. The removal of apolipoprotein E (APOE) from the gene ensemble led to a decline in predictive performance of the logistic regression classifier (from mean AUROC 0.85 [95% CI, 0.84-0.86] to 0.74 [95% CI, 0.73-0.75]; adjusted P = .001 [Tukey test]). Orthogonal testing of APOE expression level with RT-qPCR showed that APOE expression was higher in patients with corneal involvement compared to patients without (median [IQR], 0.23 [0.04-0.47] vs 0.04 [0.02-0.06]; P = .004 [Mann-Whitney U test]). Using a Youden index of 0.23 Δ threshold cycle, APOE had a sensitivity of 56% (95% CI, 33-77) and a specificity of 88% (95% CI, 79-93) in 106 samples with conjunctivitis at Aravind, India (P < .001 [Fisher exact test]). When applied to a different patient population in Thailand, the same criteria could discriminate between disease states (58 samples; sensitivity, 47%; 95% CI, 30-64 and specificity, 93%; 95% CI, 77-99; P = .001 [Fisher exact test])., Conclusions and Relevance: The results from this study suggest that the host conjunctival immune response can be meaningfully interrogated to identify biomarkers for ocular surface diseases.
- Published
- 2024
- Full Text
- View/download PDF
31. Compliance with tetracycline eye ointment during annual mass drug administration for trachoma control in the Amhara region, Ethiopia.
- Author
-
Aragie S, Shiferaw A, Sata E, Hailu D, Dagnew A, Zeru T, Abebe A, Tadesse Z, Wittberg DM, Thompson IJB, Lietman TM, Nash SD, Jensen KA, Callahan EK, and Keenan JD
- Abstract
Objectives: A 6-week course of tetracycline eye ointment is an alternative to single -dose oral azithromycin in annual mass drug administration for trachoma control. Compliance with the recommended tetracycline eye ointment regimen has not been well characterised when administered as part of a trachoma control program., Methods: A routine mass drug administration for trachoma was carried out in 40 communities in the Amhara region of Ethiopia. Two tubes of tetracycline eye ointment, to be administered twice daily for 6 weeks, was offered to all children under 6 months of age, to pregnant women who declined to take azithromycin, and to all individuals with a macrolide allergy. Seven weeks following the mass drug administration, a treatment compliance survey was performed for all community members documented to have received tetracycline eye ointment during the mass drug administration., Results: Of the 491 individuals documented as having received tetracycline eye ointment from the treatment records, 367 completed the survey, of which 214 recalled being offered tetracycline eye ointment. A total of 105 (49%) respondents reported taking ≥1 daily dose of tetracycline eye ointment on most days of the week for at least the first week. Only 20 (9%) respondents reported taking at least 1 tetracycline eye ointment dose per week for 6 weeks. The most common reasons for low compliance included 'saving it for a future infection' and 'stopped because I (or my child) seemed healthy'. The odds of low compliance were greater for those who reported not having adequate counselling (e.g., odds ratio [OR] 5.3, 95% CI 2.5-28.9 when low compliance was defined as not taking a tetracycline eye ointment dose for most days of at least the first week)., Conclusions: Compliance with tetracycline eye ointment was low when administered by a trachoma program during a routine mass drug administration, especially for those reporting inadequate counselling. Further research with a larger sample size and varied settings is warranted to better understand and improve compliance., (© 2024 The Authors Tropical Medicine & International Health published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
32. Etiologies of Infectious Keratitis in Malawi.
- Author
-
Kalua K, Misanjo ES, Lietman TM, Ruder K, Zhong L, Chen C, Liu Y, Yu D, Abraham T, Wu N, Yan D, Hinterwirth A, Doan T, and Seitzman GD
- Abstract
Infectious keratitis is a leading cause of corneal blindness worldwide with little information known about causative etiologies in Malawi, Africa. This area is resource-limited with ophthalmologist and microbiology services. The Department of Ophthalmology at the Kamuzu College of Health Sciences in Blantyre, Malawi, is a participating site of an international corneal ulcer consortium, capriCORN (Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the CORNea). In this study, 50 patients with corneal ulcers were swabbed for pathogen identification using RNA-sequencing. Corneal trauma was reported in 41% and 19% of the patients worked in agriculture. A pathogen was identified in 58% of the cases. Fungal pathogens predominated, followed by viruses and bacteria. Aspergillus, Fusarium, HSV-1, and Gardnerella were the most common pathogens detected. 50% of patients reported treatment with an antibiotic before presentation. Pathogens unusual for infectious keratitis, such as Subramaniula asteroids, Aureobasidium pullulans, and Gardnerella vaginalis, were also detected.
- Published
- 2024
- Full Text
- View/download PDF
33. Neonatal Azithromycin Exposure and Childhood Growth: Long-Term Follow-Up of a Randomized Controlled Trial.
- Author
-
Bountogo M, Ouermi L, Dah C, Sié A, Coulibaly B, Zakane A, Ouedraogo T, Ouattara M, Lebas E, Fetterman I, Kimfuema A, Doan T, Lietman TM, and Oldenburg CE
- Abstract
Single-dose azithromycin is being considered by the WHO as an intervention for prevention of child mortality. However, concerns have emerged related to longer term unintended consequences of early life antibiotic use, particularly among infants. We conducted a long-term follow-up in a random sample of children who had been enrolled in a trial of neonatal azithromycin versus placebo for prevention of mortality to assess whether neonatal azithromycin exposure led to differences in child growth up to 4 years of age. We found no evidence of a difference in any anthropometric outcome among children who had received a single oral dose of azithromycin compared with placebo during the neonatal period. These results do not support long-term growth-promoting or deleterious effects of early life azithromycin exposure.
- Published
- 2024
- Full Text
- View/download PDF
34. Photographic grading to evaluate facial cleanliness and trachoma among children in Amhara region, Ethiopia.
- Author
-
Caleon RL, Admassu F, Aragie S, Hailu D, Dagnew A, Zeru T, Wittberg DM, Thompson IJB, Abdu S, Beyecha S, Birhanu T, Getachew H, Getnet B, Kabtu E, Shibiru M, Tekew S, Wondimteka B, Lietman TM, Nash SD, Freeman MC, and Keenan JD
- Subjects
- Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Chlamydia trachomatis isolation & purification, Chlamydia trachomatis genetics, Cross-Sectional Studies, Ethiopia epidemiology, Conjunctiva microbiology, Conjunctiva pathology, Face microbiology, Face pathology, Hygiene, Photography, Trachoma epidemiology, Trachoma microbiology
- Abstract
Background: Promotion of facial cleanliness is recommended for the elimination of blinding trachoma, largely because of observational studies that have found an association between various measures of facial uncleanliness and trachoma. However, when a field grader assesses both facial cleanliness and trachoma, associations may be biased. Assessment of photographs of the face and conjunctiva by masked graders may provide a less biased estimate of the relationship between facial cleanliness and trachoma., Methods: Face photographs, conjunctival photographs, and conjunctival swabs were obtained on a random sample of 0-9-year-old children from each of 40 communities in Amhara region, Ethiopia. Face photographs were assessed for the presence of seven measures of an unclean face (i.e., wet nasal discharge, dry nasal discharge, wet ocular discharge, dry ocular discharge, food, dust/dirt, and flies) by three independent masked photo-graders. Conjunctival photographs were similarly graded in a masked fashion for signs of clinically active trachoma. Conjunctival swabs were processed for Chlamydia trachomatis DNA., Results: Of 2073 children with complete data, 808 (39%) had evidence of clinically active trachoma, 150 (7%) had evidence of ocular chlamydia infection, and 2524 (91%) had at least one measure of an unclean face. Dry ocular discharge had the strongest association with clinically active trachoma (age- and sex-adjusted prevalence ratio [PR] 1.4, 95% CI 1.2-1.6) and ocular chlamydia infection (PR 1.9, 95%CI 1.3-2.9), although significant associations were observed between each of the measures of facial uncleanliness and trachoma., Conclusions: Masked assessment of face and conjunctival photographs confirmed prior observational studies that have noted associations between various measures of facial uncleanliness and trachoma. The causal relationship between facial uncleanliness and trachoma is unclear since many features used to measure facial cleanliness (e.g., ocular discharge, nasal discharge, and flies) could be consequences of antecedent ocular chlamydia infection., Trial Registration: NCT02754583, clinicaltrials.gov., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Caleon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
35. Heterogenous pathogen profile associated with acute conjunctivitis in Nepal.
- Author
-
Chaudhary M, Sitaula S, Ruder K, Chen C, Zhong L, Heng Lu Y, Abraham T, Yu D, Hinterwirth A, Lietman TM, Doan T, and Seitzman GD
- Subjects
- Nepal epidemiology, Humans, Prospective Studies, Male, Female, Adult, Middle Aged, Young Adult, Adolescent, Acute Disease, Child, Aged, Conjunctivitis virology, RNA Viruses genetics, Conjunctiva virology, Child, Preschool, COVID-19 epidemiology, High-Throughput Nucleotide Sequencing, SARS-CoV-2
- Abstract
Background: Infectious conjunctivitis is common in Nepal., Materials and Methods: This prospective study recruited 60 patients with presumed acute infectious conjunctivitis from the B.P. Koirala Lions Center for Ophthalmic Studies in Kathmandu, Nepal. Swabs from the conjunctiva and anterior nares were processed for metagenomic RNA deep sequencing (RNA-seq)., Results: Pathogens were identified in 55% of cases. RNA viruses were the most common pathogen class identified. Severe acute respiratory syndrome coronavirus 2 was the most common RNA virus identified., Conclusions: Acute infectious conjunctivitis varies by location. Contrary to expectations, RNA viruses predominated. Repeat surveillance may be useful and RNA-seq allows for detection of the unexpected pathogen including RNA viruses., (© The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.)
- Published
- 2024
- Full Text
- View/download PDF
36. Human Conjunctival Transcriptome in Acanthamoeba Keratitis: An Exploratory Study.
- Author
-
Seitzman GD, Keenan JD, Lietman TM, Ruder K, Zhong L, Chen C, Liu Y, Yu D, Abraham T, Hinterwirth A, and Doan T
- Subjects
- Humans, Male, Adult, Female, Middle Aged, Acanthamoeba genetics, Gene Expression Profiling, Young Adult, Microscopy, Confocal, Aged, Sequence Analysis, RNA, Acanthamoeba Keratitis parasitology, Acanthamoeba Keratitis diagnosis, Acanthamoeba Keratitis genetics, Transcriptome, Conjunctiva parasitology, Conjunctiva metabolism
- Abstract
Purpose: The purpose of this study was to identify conjunctival transcriptome differences in patients with Acanthamoeba keratitis compared with keratitis with no known associated pathogen., Methods: The host conjunctival transcriptome of 9 patients with Acanthamoeba keratitis (AK) is compared with the host conjunctival transcriptome of 13 patients with pathogen-free keratitis. Culture and/or confocal confirmed Acanthamoeba in 8 of 9 participants with AK who underwent metagenomic RNA sequencing as the likely pathogen. Cultures were negative in all 13 cases where metagenomic RNA sequencing did not identify a pathogen., Results: Transcriptome analysis identified 36 genes differently expressed between patients with AK and patients with presumed sterile, or pathogen-free, keratitis. Gene enrichment analysis revealed that some of these genes participate in several biologic pathways important for cellular signaling, ion transport and homeostasis, glucose transport, and mitochondrial metabolism. Notable relatively differentially expressed genes with potential relevance to Acanthamoeba infection included CPS1 , SLC35B4 , STEAP2 , ATP2B2 , NMNAT3 , and AKAP12 ., Conclusions: This research suggests that the local transcriptome in Acanthamoeba keratitis may be sufficiently robust to be detected in the conjunctiva and that corneas infected with Acanthamoeba may be distinguished from the inflamed cornea where no pathogen was identified. Given the low sensitivity for corneal cultures, identification of differentially expressed genes may serve as a suggestive transcriptional signature allowing for a complementary diagnostic technique to identify this blinding parasite. Knowledge of differentially expressed genes may also direct investigation of disease pathophysiology and suggest novel pathways for therapeutic targets., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Assessment of spillover of antimicrobial resistance to untreated children 7 to 12 years old after mass drug administration of azithromycin for child survival in Niger: a secondary analysis of the MORDOR cluster-randomized trial.
- Author
-
Peterson B, Arzika AM, Amza A, Maliki R, Mankara Karamba A, Moussa M, Kemago M, Liu Z, Houpt E, Liu J, Pholwat S, Doan T, Porco T, Keenan JD, Lietman TM, and O'Brien KS
- Abstract
Background: The risk of antibiotic resistance is complicated by the potential for spillover effects from one treated population to another. Azithromycin mass drug administration programs report higher rates of antibiotic resistance among treatment arms in targeted groups. This study aims to understand the risk of spillover of antibiotic resistance to non-target groups in these programs., Methods: Data was used from a cluster-randomized trial comparing the effect of biannual azithromycin and placebo distribution to children 1-59 months on child mortality. Nasopharyngeal samples from untreated children 7-12 years old were tested for genetic determinants of macrolide resistance (primary outcome) and resistance to other antibiotic classes (secondary outcomes). Linear regression was used to compare the community-level mean difference in prevalence by arm at the 24-month timepoint adjusting for baseline prevalence., Results: 1,103 children 7-12 years old in 30 communities were included in the analysis (15 azithromycin, 15 placebo). Adjusted mean differences in prevalence of resistance determinants for macrolides, beta-lactams and tetracyclines were 3.4% (95% CI -4.1% to 10.8%, P-value 0.37), -1.2% (95% CI -7.9% to 5.5%, P-value 0.72), and -3.3% (95% CI -9.5% to 2.8%, P-value 0.61), respectively., Conclusions: We were unable to demonstrate a statistically significant increase in macrolide resistance determinants in untreated groups in an azithromycin mass drug administration program. While the result might be consistent with a small spillover effect, this study was not powered to detect such a small difference. Larger studies are warranted to better understand the potential for spillover effects within these programs., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
38. Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).
- Author
-
Arzika AM, Abdou A, Maliki R, Beido N, Kadri B, Harouna AN, Galo AN, Alio MK, Lebas E, Oldenburg CE, O'Brien KS, Chen C, Zhong L, Zhou Z, Yan D, Hinterwirth A, Keenan JD, Porco TC, Lietman TM, and Doan T
- Subjects
- Humans, Niger, Child, Preschool, Infant, Female, Male, Child Mortality, Azithromycin therapeutic use, Anti-Bacterial Agents therapeutic use, Drug Resistance, Bacterial, Macrolides therapeutic use, Mass Drug Administration
- Abstract
Background: Randomized controlled trials found that twice-yearly mass azithromycin administration (MDA) reduces childhood mortality, presumably by reducing infection burden. World Health Organization (WHO) issued conditional guidelines for mass azithromycin administration in high-mortality settings in sub-Saharan Africa given concerns for antibiotic resistance. While prolonged twice-yearly MDA has been shown to increase antibiotic resistance in small randomized controlled trials, the objective of this study was to determine if macrolide and non-macrolide resistance in the gut increases with the duration of azithromycin MDA in a larger setting., Methods and Findings: The Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) study was conducted in Niger from December 2014 to June 2020. It was a cluster-randomized trial of azithromycin (A) versus placebo (P) aimed at evaluating childhood mortality. This is a sub-study in the MORDOR trial to track changes in antibiotic resistance after prolonged azithromycin MDA. A total of 594 communities were eligible. Children 1 to 59 months in 163 randomly chosen communities were eligible to receive treatment and included in resistance monitoring. Participants, staff, and investigators were masked to treatment allocation. At the conclusion of MORDOR Phase I, by design, all communities received an additional year of twice-yearly azithromycin treatments (Phase II). Thus, at the conclusion of Phase II, the treatment history (1 letter per 6-month period) for the participating communities was either (PP-PP-AA) or (AA-AA-AA). In Phase III, participating communities were then re-randomized to receive either another 3 rounds of azithromycin or placebo, thus resulting in 4 treatment histories: Group 1 (AA-AA-AA-AA-A, N = 51), Group 2 (PP-PP-AA-AA-A, N = 40), Group 3 (AA-AA-AA-PP-P, N = 27), and Group 4 (PP-PP-AA-PP-P, N = 32). Rectal swabs from each child (N = 5,340) were obtained 6 months after the last treatment. Each child contributed 1 rectal swab and these were pooled at the community level, processed for DNA-seq, and analyzed for genetic resistance determinants. The primary prespecified outcome was macrolide resistance determinants in the gut. Secondary outcomes were resistance to beta-lactams and other antibiotic classes. Communities recently randomized to azithromycin (groups 1 and 2) had significantly more macrolide resistance determinants than those recently randomized to placebo (groups 3 and 4) (fold change 2.18, 95% CI 1.5 to 3.51, Punadj < 0.001). However, there was no significant increase in macrolide resistance in communities treated 4.5 years (group 1) compared to just the most recent 2.5 years (group 2) (fold change 0.80, 95% CI 0.50 to 1.00, Padj = 0.010), or between communities that had been treated for 3 years in the past (group 3) versus just 1 year in the past (group 4) (fold change 1.00, 95% CI 0.78 to 2.35, Padj = 0.52). We also found no significant differences for beta-lactams or other antibiotic classes. The main limitations of our study were the absence of phenotypic characterization of resistance, no complete placebo arm, and no monitoring outside of Niger limiting generalizability., Conclusions: In this study, we observed that mass azithromycin distribution for childhood mortality among preschool children in Niger increased macrolide resistance determinants in the gut but that resistance may plateau after 2 to 3 years of treatment. Co-selection to other classes needs to be monitored., Trial Registration: NCT02047981 https://classic.clinicaltrials.gov/ct2/show/NCT02047981., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Arzika et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
39. District-Level Forecast of Achieving Trachoma Elimination as a Public Health Problem By 2030: An Ensemble Modelling Approach.
- Author
-
Srivathsan A, Abdou A, Al-Khatib T, Apadinuwe SC, Badiane MD, Bucumi V, Chisenga T, Kabona G, Kabore M, Kanyi SK, Bella L, M'po N, Masika M, Minnih A, Sitoe HM, Mishra S, Olobio N, Omar FJ, Phiri I, Sanha S, Seife F, Sharma S, Tekeraoi R, Traore L, Watitu T, Bol YY, Borlase A, Deiner MS, Renneker KK, Hooper PJ, Emerson PM, Vasconcelos A, Arnold BF, Porco TC, Hollingsworth TD, Lietman TM, and Blumberg S
- Subjects
- Humans, Child, Preschool, Infant, Child, Prevalence, Models, Statistical, Mass Drug Administration, World Health Organization, Global Health, Male, Female, Trachoma epidemiology, Trachoma prevention & control, Disease Eradication methods, Forecasting, Public Health
- Abstract
Assessing the feasibility of 2030 as a target date for global elimination of trachoma, and identification of districts that may require enhanced treatment to meet World Health Organization (WHO) elimination criteria by this date are key challenges in operational planning for trachoma programmes. Here we address these challenges by prospectively evaluating forecasting models of trachomatous inflammation-follicular (TF) prevalence, leveraging ensemble-based approaches. Seven candidate probabilistic models were developed to forecast district-wise TF prevalence in 11 760 districts, trained using district-level data on the population prevalence of TF in children aged 1-9 years from 2004 to 2022. Geographical location, history of mass drug administration treatment, and previously measured prevalence data were included in these models as key predictors. The best-performing models were included in an ensemble, using weights derived from their relative likelihood scores. To incorporate the inherent stochasticity of disease transmission and challenges of population-level surveillance, we forecasted probability distributions for the TF prevalence in each geographic district, rather than predicting a single value. Based on our probabilistic forecasts, 1.46% (95% confidence interval [CI]: 1.43-1.48%) of all districts in trachoma-endemic countries, equivalent to 172 districts, will exceed the 5% TF control threshold in 2030 with the current interventions. Global elimination of trachoma as a public health problem by 2030 may require enhanced intervention and/or surveillance of high-risk districts., Competing Interests: Potential conflicts of interest. A. V. reports funding for this supplement provided by the BMGF via INV-030046 to the NTD Modelling Consortium, funding for this supplement provided by the Li Ka Shing Foundation via Professor Hollingsworth research funding, and funding for this project provided by Children's Investment Foundation (CIFF) Accelerate Trachoma Elimination funding. T. D. H. reports that the study was funded by the Bill & Melinda Gates Foundation via grant number INV-030046 to the NTD Modelling Consortium: Informing program decision-making. T. P. reports funding from the NEI, NIH (NIH NEI grant number R01EY025350) and funding from CIFF and the Bill & Melinda Gates Foundation (grant number INV-030046). T. L. reports funding from the NEI and NIH (grant number R01EY025350) and funding from CIFF and the Bill & Melinda Gates Foundation (grant number INV-030046). S. B. is also supported by the National Institute of General Medical Sciences [NIH NIGMS R35GM147702] and the National Eye Institute [NIH NEI K12 EY031372] at the NIH. P. J. H. reports salary and travel support from Pfizer, Inc., through a grant to The Task Force for Global Health and a donation of the antibiotic azithromycin from Pfizer through The Task Force for Global Health for global trachoma elimination purposes. K. K. R. reports being an employee of the International Trachoma Initiative, a program of The Task Force for Global Health, which receives an operating budget and research funds from Pfizer Inc, the manufacturers of Zithromax (azithromycin). B. F. A. reports funding to their institution from NIH National Institute of Allergy and Infectious Diseases (NIAID), payments to cover airfare and hotel to attend scientific meetings in Baltimore and Atlanta from the Bill & Melinda Gates Foundation, and honoraria payments for serving on a trial DSMB from the NIH. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
40. Neonatal anthropometric indicators of infant growth and mortality in Burkina Faso.
- Author
-
Bountogo M, Sié A, Zakane A, Compaoré G, Ouédraogo T, Lebas E, O'Brien KS, Lietman TM, and Oldenburg CE
- Subjects
- Humans, Burkina Faso epidemiology, Infant, Male, Female, Infant, Newborn, Body Height, Infant, Low Birth Weight, Azithromycin administration & dosage, Azithromycin therapeutic use, Child Development, Wasting Syndrome epidemiology, Wasting Syndrome mortality, Body Weight, Logistic Models, Anthropometry, Growth Disorders epidemiology, Growth Disorders mortality, Infant Mortality, Thinness epidemiology, Thinness mortality, Birth Weight
- Abstract
Objective: Most evidence supporting screening for undernutrition is for children aged 6-59 months. However, the highest risk of mortality and highest incidence of wasting occurs in the first 6 months of life. We evaluated relationships between neonatal anthropometric indicators, including birth weight, weight-for-age Z -score (WAZ), weight-for-length Z-score (WLZ), length-for-age Z -score (LAZ) and mid-upper arm circumference (MUAC) and mortality and growth at 6 months of age among infants in Burkina Faso., Design: Data arose from a randomised controlled trial evaluating neonatal azithromycin administration for the prevention of child mortality. We evaluated relationships between baseline anthropometric measures and mortality, wasting (WLZ < -2), stunting (LAZ < -2) and underweight (WAZ < -2) at 6 months of age were estimated using logistic regression models adjusted for the child's age and sex., Setting: Five regions of Burkina Faso., Participants: Infants aged 8-27 d followed until 6 months of age., Results: Of 21 832 infants enrolled in the trial, 7·9 % were low birth weight (<2500 g), 13·3 % were wasted, 7·7 % were stunted and 7·4 % were underweight at enrolment. All anthropometric deficits were associated with mortality by 6 months of age, with WAZ the strongest predictor (WAZ < -2 to ≥ -3 at enrolment v . WAZ ≥ -2: adjusted OR, 3·91, 95 % CI, 2·21, 6·56). Low WAZ was also associated with wasting, stunting, and underweight at 6 months., Conclusions: Interventions for identifying infants at highest risk of mortality and growth failure should consider WAZ as part of their screening protocol.
- Published
- 2024
- Full Text
- View/download PDF
41. Locality is the strongest predictor of expert performance in image-based differentiation of bacterial and fungal corneal ulcers from India.
- Author
-
Rosenberg CR, Prajna V, Srinivasan MK, Lalitha PC, Krishnan T, Rajaraman R, Venugopal A, Acharya N, Seitzman GD, Rose-Nussbaumer J, Woodward MA, Lietman TM, Campbell JP, Keenan JD, and Redd TK
- Subjects
- Humans, Ulcer, Reproducibility of Results, Bacteria, India epidemiology, Corneal Ulcer diagnosis, Corneal Ulcer epidemiology, Corneal Ulcer complications, Eye Infections, Bacterial diagnosis, Eye Infections, Bacterial epidemiology, Eye Infections, Bacterial etiology, Eye Infections, Fungal diagnosis, Eye Infections, Fungal epidemiology, Eye Infections, Fungal etiology
- Abstract
Purpose: This study sought to identify the sources of differential performance and misclassification error among local (Indian) and external (non-Indian) corneal specialists in identifying bacterial and fungal keratitis based on corneal photography., Methods: This study is a secondary analysis of survey data assessing the ability of corneal specialists to identify acute bacterial versus fungal keratitis by using corneal photography. One-hundred images of 100 eyes from 100 patients with acute bacterial or fungal keratitis in South India were previously presented to an international cohort of cornea specialists for interpretation over the span of April to July 2021. Each expert provided a predicted probability that the ulcer was either bacterial or fungal. Using these data, we performed multivariable linear regression to identify factors predictive of expert performance, accounting for primary practice location and surrogate measures to infer local fungal ulcer prevalence, including locality, latitude, and dew point. In addition, Brier score decomposition was used to determine experts' reliability ("calibration") and resolution ("boldness") and were compared between local (Indian) and external (non-Indian) experts., Results: Sixty-six experts from 16 countries participated. Indian practice location was the only independently significant predictor of performance in multivariable linear regression. Resolution among Indian experts was significantly better (0.08) than among non-Indian experts (0.01; P < 0.001), indicating greater confidence in their predictions. There was no significant difference in reliability between the two groups ( P = 0.40)., Conclusion: Local cornea experts outperformed their international counterparts independent of regional variability in tropical risk factors for fungal keratitis. This may be explained by regional characteristics of infectious ulcers with which local corneal specialists are familiar., (Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.)
- Published
- 2024
- Full Text
- View/download PDF
42. Risk factors for corneal abrasions in Nepal: a community-based study.
- Author
-
Brekke SR, Giri P, Byanju R, Pradhan S, Bhandari G, Bhandari S, Kandel RP, Poudyal B, Gonzales JA, Srinivasan M, Upadhyay M, Whitcher JP, O'Brien KS, Lietman TM, and Keenan JD
- Subjects
- Humans, Cross-Sectional Studies, Nepal, Prospective Studies, Risk Factors, Corneal Injuries
- Abstract
Background: South Asia is experiencing rapid urbanization, which may be changing the risk factor profile for ocular trauma. The objective of this study was to compare risk factors for traumatic corneal abrasions in rural versus urban Nepal, and to assess if any risk factors were associated with a poor outcome., Methods: In a prospective, cross-sectional, community-based study performed as part of a cluster-randomized trial, community health workers from Nepal were trained to diagnose and treat traumatic corneal abrasions. Participants with an abrasion were invited to complete a risk factor survey. The main exposure variable was the object of eye injury, stratified by rural-urban residence. The main outcome measure was a lack of corneal healing after a three-day course of antimicrobials., Results: Of 3657 participants diagnosed with a corneal abrasion, 2265 completed a survey. Eye trauma occurred most frequently during agricultural activities. The most common object of injury was vegetative matter, accounting for approximately 40% of injuries in rural, peri-urban, and urban communities. Wood injuries were more common in rural communities (24%) compared with urban or peri-urban communities (13%). Eye injury from an animal was more likely to result in a non-healing corneal abrasion after 3 days of treatment compared with other types of trauma (prevalence ratio 2.59, 95%CI 1.16-5.76)., Conclusions: Health promotion activities for prevention of corneal ulcers in Nepal should focus on agricultural trauma in both rural and urban areas. Community members experiencing eye trauma from an animal may benefit from early referral to an eye clinic., (© 2023. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
- Published
- 2024
- Full Text
- View/download PDF
43. Efficacy of Single-Dose Azithromycin for Ocular Chlamydial Infection: A Longitudinal Study.
- Author
-
Pondicherry N, Abdou A, Kadri B, Nassirou B, Cotter SY, Varnado NE, Porco TC, West SK, Lietman TM, and Keenan JD
- Subjects
- Humans, Child, Preschool, Infant, Female, Male, Longitudinal Studies, Treatment Outcome, Chlamydia Infections drug therapy, Niger, Infant, Newborn, Azithromycin administration & dosage, Azithromycin therapeutic use, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Trachoma drug therapy, Chlamydia trachomatis drug effects
- Abstract
Millions of doses of azithromycin are distributed each year for trachoma, yet the treatment efficacy of a single dose of azithromycin for ocular Chlamydia infection has not been well characterized. In this study, four villages in Niger received a mass azithromycin distribution for trachoma. All 426 children aged 0-5 years residing in the study villages were offered conjunctival swabbing every 6 months to test for ocular Chlamydia trachomatis. Among the children infected with ocular Chlamydia before treatment, 6% (95% CI: 2-15%) tested positive for ocular Chlamydia infection 6 months later, and 15% (95% CI: 7-28%) tested positive 12 months later. The most important predictor of post-treatment ocular Chlamydia infection was pretreatment ocular Chlamydia infection (relative risk: 3.5, 95% CI: 1.3-9.4). Although the 6-monthly monitoring schedule was suboptimal for testing the treatment efficacy of an antibiotic, these findings are nonetheless consistent with high treatment efficacy of a single dose of azithromycin and suggest that additional interventions might be most effective if targeted to those children infected prior to treatment.
- Published
- 2024
- Full Text
- View/download PDF
44. Ocular Signs and Testing Most Compatible with Sarcoidosis-Associated Uveitis: A Latent Class Analysis.
- Author
-
Xiong F, Acharya N, Rao N, Mochizuki M, Lietman TM, and Gonzales JA
- Abstract
Purpose: This study aims to explore the potential subgroups of sarcoidosis-associated uveitis (SAU) within a multicenter cohort of uveitis participants., Design: Cross-sectional study., Participants: A cohort of 826 uveitis patients from a uveitis registry from 19 clinical centers in 12 countries between January 2011 and April 2015., Methods: We employed a latent class analysis (LCA) incorporating recommended tests and clinical signs from the revised International Workshop on Ocular Sarcoidosis (IWOS) to identify potential SAU subgroups within the multicenter uveitis cohort. Additionally, we assessed the performance of the individual tests and clinical signs in classifying the potential subclasses., Main Outcome Measures: Latent subtypes of SAU., Results: Among 826 participants included in this analysis, the 2-class LCA model provided a best fit, with the lowest Bayesian information criteria of 7218.7 and an entropy of 0.715. One class, consisting of 548 participants, represented the non-SAU, whereas the second class, comprised of 278 participants, was most representative of SAU. Snowballs/string of pearls vitreous opacities had the best test performance for classification, followed by bilaterality and bilateral hilar lymphadenopathy (BHL). The combination of 4 tests with the highest classification importance, including snowballs/string of pearls vitreous opacities, periphlebitis and/or macroaneurysm, bilaterality, and BHL, demonstrated a sensitivity of 84.8% and a specificity of 95.4% in classifying the SAU subtypes. In the exploratory analysis of the 3-class LCA model, which had comparable fit indices as the 2-class model, we identified a candidate non-SAU subtype, candidate SAU subtype with pulmonary involvement, and a candidate SAU with less pulmonary involvement., Conclusions: Latent class modeling, incorporating tests and clinical signs from the revised IWOS criteria, effectively identified a subset of participants with clinical features indicative of SAU. Though the sensitivity of individual ocular signs or tests was not perfect, using a combination of tests provided a satisfactory performance in classifying the SAU subclasses identified by the 2-class LCA model. Notably, the classes identified by the 3-class LCA model, including a non-SAU subtype, an SAU subtype with pulmonary involvement, and an SAU subtype with less pulmonary involvement, may have potential implication for clinical practice, and hence should be validated in further research., Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article., (© 2024 by the American Academy of Ophthalmology.)
- Published
- 2024
- Full Text
- View/download PDF
45. Use of Large Language Models to Assess the Likelihood of Epidemics From the Content of Tweets: Infodemiology Study.
- Author
-
Deiner MS, Deiner NA, Hristidis V, McLeod SD, Doan T, Lietman TM, and Porco TC
- Subjects
- Humans, United States, Infodemiology, Disease Outbreaks, Language, Epidemics, Conjunctivitis, Social Media
- Abstract
Background: Previous work suggests that Google searches could be useful in identifying conjunctivitis epidemics. Content-based assessment of social media content may provide additional value in serving as early indicators of conjunctivitis and other systemic infectious diseases., Objective: We investigated whether large language models, specifically GPT-3.5 and GPT-4 (OpenAI), can provide probabilistic assessments of whether social media posts about conjunctivitis could indicate a regional outbreak., Methods: A total of 12,194 conjunctivitis-related tweets were obtained using a targeted Boolean search in multiple languages from India, Guam (United States), Martinique (France), the Philippines, American Samoa (United States), Fiji, Costa Rica, Haiti, and the Bahamas, covering the time frame from January 1, 2012, to March 13, 2023. By providing these tweets via prompts to GPT-3.5 and GPT-4, we obtained probabilistic assessments that were validated by 2 human raters. We then calculated Pearson correlations of these time series with tweet volume and the occurrence of known outbreaks in these 9 locations, with time series bootstrap used to compute CIs., Results: Probabilistic assessments derived from GPT-3.5 showed correlations of 0.60 (95% CI 0.47-0.70) and 0.53 (95% CI 0.40-0.65) with the 2 human raters, with higher results for GPT-4. The weekly averages of GPT-3.5 probabilities showed substantial correlations with weekly tweet volume for 44% (4/9) of the countries, with correlations ranging from 0.10 (95% CI 0.0-0.29) to 0.53 (95% CI 0.39-0.89), with larger correlations for GPT-4. More modest correlations were found for correlation with known epidemics, with substantial correlation only in American Samoa (0.40, 95% CI 0.16-0.81)., Conclusions: These findings suggest that GPT prompting can efficiently assess the content of social media posts and indicate possible disease outbreaks to a degree of accuracy comparable to that of humans. Furthermore, we found that automated content analysis of tweets is related to tweet volume for conjunctivitis-related posts in some locations and to the occurrence of actual epidemics. Future work may improve the sensitivity and specificity of these methods for disease outbreak detection., (©Michael S Deiner, Natalie A Deiner, Vagelis Hristidis, Stephen D McLeod, Thuy Doan, Thomas M Lietman, Travis C Porco. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 01.03.2024.)
- Published
- 2024
- Full Text
- View/download PDF
46. Anterior Segment OCT for Detection of Narrow Angles: A Community-Based Diagnostic Accuracy Study.
- Author
-
Pradhan S, Sah RK, Bhandari G, Bhandari S, Byanju R, Kandel RP, Thompson IJB, Stevens VM, Aromin KM, Oatts JT, Ou Y, Lietman TM, O'Brien KS, and Keenan JD
- Subjects
- Humans, Tomography, Optical Coherence methods, Cross-Sectional Studies, Trabecular Meshwork, Sensitivity and Specificity, Glaucoma, Angle-Closure diagnosis, Glaucoma diagnosis
- Abstract
Purpose: To assess the diagnostic accuracy of anterior segment OCT (AS-OCT) screening for detecting gonioscopically narrow angles., Design: Population-based cross-sectional study., Participants: A stratified random sample of individuals aged ≥ 60 years, selected from a door-to-door census performed in low-lying Nepal., Testing: Participants underwent AS-OCT, posterior segment OCT, and intraocular pressure (IOP) testing in the community. Those meeting referral criteria in either eye were invited to have a comprehensive eye examination including gonioscopy. Referral criteria included (i) the lowest 2.5% of AS-OCT measurements, (ii) retinal OCT results suggestive of glaucomatous optic neuropathy, diabetic retinopathy, or age-related macular degeneration, and (iii) elevated IOP., Main Outcome Measures: Sensitivity and specificity of 5 semiautomated AS-OCT parameters relative to gonioscopically narrow angles, defined as the absence of visible trabecular meshwork for ≥ 180° on nonindentation gonioscopy., Results: Of 17 656 people aged ≥ 60 years enumerated from 102 communities, 12 633 (71.6%) presented for AS-OCT testing. Referral was recommended for 697 participants based on AS-OCT criteria and 2419 participants based on other criteria, of which 858 had gonioscopy performed by a glaucoma specialist. Each of the 5 AS-OCT parameters offered good diagnostic information for predicting eyes with gonioscopically narrow angles, with areas under the receiver operating characteristic curve ranging from 0.85 to 0.89. The angle opening distance at 750 μm from the scleral spur (AOD750) provided the most diagnostic information, providing an optimal sensitivity of 87% (95% confidence interval [CI], 75%-96%) and specificity of 77% (71%-83%) at a cutpoint of 367 μm, and a sensitivity of 65% (95% CI, 54%-74%) when specificity was constrained to 90% (cutpoint, 283 μm)., Conclusions: On AS-OCT, the AOD750 parameter detected approximately two-thirds of cases of gonioscopically narrow angles when test specificity was set to 90%. Although such a sensitivity may not be sufficient when screening solely for narrow angles, AS-OCT requires little additional effort if posterior segment OCT is already being performed and thus could provide incremental benefit when performing OCT-based screening., Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article., (Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial.
- Author
-
Oldenburg CE, Ouattara M, Bountogo M, Boudo V, Ouedraogo T, Compaoré G, Dah C, Zakane A, Coulibaly B, Bagagnan C, Hu H, O'Brien KS, Nyatigo F, Keenan JD, Doan T, Porco TC, Arnold BF, Lebas E, Sié A, and Lietman TM
- Subjects
- Humans, Burkina Faso epidemiology, Chemoprevention methods, Chemoprevention statistics & numerical data, Seasons, Infant, Child, Preschool, Azithromycin supply & distribution, Azithromycin therapeutic use, Child Mortality trends, Malaria epidemiology, Malaria mortality, Malaria prevention & control, Anti-Bacterial Agents supply & distribution, Anti-Bacterial Agents therapeutic use
- Abstract
Importance: Repeated mass distribution of azithromycin has been shown to reduce childhood mortality by 14% in sub-Saharan Africa. However, the estimated effect varied by location, suggesting that the intervention may not be effective in different geographical areas, time periods, or conditions., Objective: To evaluate the efficacy of twice-yearly azithromycin to reduce mortality in children in the presence of seasonal malaria chemoprevention., Design, Setting, and Participants: This cluster randomized placebo-controlled trial evaluating the efficacy of single-dose azithromycin for prevention of all-cause childhood mortality included 341 communities in the Nouna district in rural northwestern Burkina Faso. Participants were children aged 1 to 59 months living in the study communities., Interventions: Communities were randomized in a 1:1 ratio to receive oral azithromycin or placebo distribution. Children aged 1 to 59 months were offered single-dose treatment twice yearly for 3 years (6 distributions) from August 2019 to February 2023., Main Outcomes and Measures: The primary outcome was all-cause childhood mortality, measured during a twice-yearly enumerative census., Results: A total of 34 399 children (mean [SD] age, 25.2 [18] months) in the azithromycin group and 33 847 children (mean [SD] age, 25.6 [18] months) in the placebo group were included. A mean (SD) of 90.1% (16.0%) of the censused children received the scheduled study drug in the azithromycin group and 89.8% (17.1%) received the scheduled study drug in the placebo group. In the azithromycin group, 498 deaths were recorded over 60 592 person-years (8.2 deaths/1000 person-years). In the placebo group, 588 deaths were recorded over 58 547 person-years (10.0 deaths/1000 person-years). The incidence rate ratio for mortality was 0.82 (95% CI, 0.67-1.02; P = .07) in the azithromycin group compared with the placebo group. The incidence rate ratio was 0.99 (95% CI, 0.72-1.36) in those aged 1 to 11 months, 0.92 (95% CI, 0.67-1.27) in those aged 12 to 23 months, and 0.73 (95% CI, 0.57-0.94) in those aged 24 to 59 months., Conclusions and Relevance: Mortality in children (aged 1-59 months) was lower with biannual mass azithromycin distribution in a setting in which seasonal malaria chemoprevention was also being distributed, but the difference was not statistically significant. The study may have been underpowered to detect a clinically relevant difference., Trial Registration: ClinicalTrials.gov Identifier: NCT03676764.
- Published
- 2024
- Full Text
- View/download PDF
48. Validation of the C-DU(KE) Calculator as a Predictor of Outcomes in Patients Enrolled in Steroids for Corneal Ulcer and Mycotic Ulcer Treatment Trials.
- Author
-
Arboleda A, Prajna NV, Lalitha P, Srinivasan M, Rajaraman R, Krishnan T, Mousa HM, Feghali J, Acharya NR, Lietman TM, Perez VL, and Rose-Nussbaumer J
- Subjects
- Humans, Antifungal Agents therapeutic use, Steroids, Ulcer drug therapy, Clinical Trials as Topic, Corneal Ulcer diagnosis, Corneal Ulcer drug therapy, Corneal Ulcer microbiology, Eye Infections, Fungal diagnosis, Eye Infections, Fungal drug therapy, Eye Infections, Fungal microbiology, Mycoses microbiology
- Abstract
Purpose: The aim of this study was to validate the C-DU(KE) calculator as a predictor of treatment outcomes on a data set derived from patients with culture-positive ulcers., Methods: C-DU(KE) criteria were compiled from a data set consisting of 1063 cases of infectious keratitis from the Steroids for Corneal Ulcer Trial (SCUT) and Mycotic Ulcer Treatment Trial (MUTT) studies. These criteria include corticosteroid use after symptoms, visual acuity, ulcer area, fungal etiology, and elapsed time to organism-sensitive therapy. Univariate analysis was performed followed by multivariable logistic regressions on culture-exclusive and culture-inclusive models to assess for associations between the variables and outcome. The predictive probability of treatment failure, defined as the need for surgical intervention, was calculated for each study participant. Discrimination was assessed using the area under the curve for each model., Results: Overall, 17.9% of SCUT/MUTT participants required surgical intervention. Univariate analysis showed that decreased visual acuity, larger ulcer area, and fungal etiology had a significant association with failed medical management. The other 2 criteria did not. In the culture-exclusive model, 2 of 3 criteria, decreased vision [odds ratio (OR) = 3.13, P < 0.001] and increased ulcer area (OR = 1.03, P < 0.001), affected outcomes. In the culture-inclusive model, 3 of 5 criteria, decreased vision (OR = 4.9, P < 0.001), ulcer area (OR = 1.02, P < 0.001), and fungal etiology (OR = 9.8, P < 0.001), affected results. The area under the curves were 0.784 for the culture-exclusive model and 0.846 for the culture-inclusive model which were comparable to the original study., Conclusions: The C-DU(KE) calculator is generalizable to a study population from large international studies primarily taking place in India. These results support its use as a risk stratification tool assisting ophthalmologists in patient management., Competing Interests: V.L. Perez has financial relationships with Alcon, Dompe, EyeGate, Kala, Trefoil, Novartis, and Oculis. The remaining authors have no conflicts of interest to disclose., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. Descemet Endothelial Thickness Comparison Trial 1 (DETECT 1): outcome masked, placebo-controlled trial comparing two types of corneal transplant surgeries and effect of rho kinase inhibitors on endothelial cell loss protocol.
- Author
-
Chamberlain W, Lin CC, Li JY, Gensheimer W, Clover J, Jeng BH, Varnado N, Abdelrahman S, Arnold BF, Lietman TM, and Rose-Nussbaumer J
- Subjects
- Humans, Descemet Membrane, rho-Associated Kinases, Quality of Life, Endothelium, Corneal, Endothelial Cells, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Fuchs' Endothelial Dystrophy surgery, Descemet Stripping Endothelial Keratoplasty adverse effects, Isoquinolines, Sulfonamides
- Abstract
Background: It remains uncertain which endothelial keratoplasty (EK) technique yields the best outcomes while maintaining safety, particularly in eyes with coexisting ocular conditions. Moreover, the impact of endothelial cell loss (ECL) on long-term graft survival requires further investigation. Adjuvant ripasudil, a rho kinase inhibitor, may address the challenge of ECL in corneal transplantation. This paper presents the protocol for the Descemet Endothelial Thickness Comparison Trial 1 (DETECT 1), a multicentre, outcome-masked, randomised, placebo-controlled, four-arm clinical trial., Methods: A total of 160 eligible patients with endothelial dysfunction will be enrolled from five participating sites in the USA. The patients will be randomly assigned in a 2×2 factorial design to one of the following treatment groups: group 1-ultrathin Descemet stripping endothelial keratoplasty (UT-DSAEK) plus topical ripasudil 0.4%; group 2-UT-DSAEK plus topical placebo; group 3-Descemet membrane endothelial keratoplasty (DMEK) plus topical ripasudil 0.4% and group 4-DMEK plus topical placebo. Primary outcomes include the best spectacle-corrected visual acuity at 12 months and ECL at 12 months. Secondary outcomes include visual acuity at different time points, vision-related quality of life, endothelial cell morphology and cost-effectiveness., Results: The study outcomes will be analysed using mixed effects linear regression models, taking into account the treatment arms and relevant covariates. Adverse events, including rebubble procedures, graft failure and graft rejection, will be documented and analysed using appropriate statistical methods., Conclusion: DETECT I aims to provide evidence on the comparative effectiveness of UT-DSAEK and DMEK, as well as the potential benefits of adjuvant topical ripasudil in reducing ECL. The results of this trial will contribute to optimising corneal transplantation techniques and improving long-term graft survival, while also exploring the cost-effectiveness of these interventions. Dissemination of findings through peer-reviewed publications and national/international meetings will facilitate knowledge translation and guide clinical practice in the field of corneal transplantation., Ethics and Dissemination: A data and safety monitoring committee (DSMC) has been empaneled by the NEI.All study protocols will be subject to review and approval by WCG IRB as the single IRB of record.This study will comply with the National Institute of Health (NIH) Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. Data from the trial will be made available on reasonable request., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
50. Single-dose azithromycin for infant growth in Burkina Faso: Prespecified secondary anthropometric outcomes from a randomized controlled trial.
- Author
-
Sié A, Ouattara M, Bountogo M, Dah C, Ouedraogo T, Boudo V, Lebas E, Hu H, Arnold BF, O'Brien KS, Lietman TM, and Oldenburg CE
- Subjects
- Child, Infant, Humans, Burkina Faso epidemiology, Weight Gain, Anti-Bacterial Agents adverse effects, Azithromycin adverse effects, Pediatric Obesity
- Abstract
Background: Antibiotic use during early infancy has been linked to childhood obesity in high-income countries. We evaluated whether a single oral dose of azithromycin administered during infant-well visits led to changes in infant growth outcomes at 6 months of age in a setting with a high prevalence of undernutrition in rural Burkina Faso., Methods and Findings: Infants were enrolled from September 25, 2019, until October 22, 2022, in a randomized controlled trial designed to evaluate the efficacy of a single oral dose of azithromycin (20 mg/kg) compared to placebo when administered during well-child visits for prevention of infant mortality. The trial found no evidence of a difference in the primary endpoint. This paper presents prespecified secondary anthropometric endpoints including weight gain (g/day), height change (mm/day), weight-for-age Z-score (WAZ), weight-for-length Z-score (WLZ), length-for-age Z-score (LAZ), and mid-upper arm circumference (MUAC). Infants were eligible for the trial if they were between 5 and 12 weeks of age, able to orally feed, and their families were planning to remain in the study area for the duration of the study. Anthropometric measurements were collected at enrollment (5 to 12 weeks of age) and 6 months of age. Among 32,877 infants enrolled in the trial, 27,298 (83%) were followed and had valid anthropometric measurements at 6 months of age. We found no evidence of a difference in weight gain (mean difference 0.03 g/day, 95% confidence interval (CI) -0.12 to 0.18), height change (mean difference 0.004 mm/day, 95% CI -0.05 to 0.06), WAZ (mean difference -0.004 SD, 95% CI -0.03 to 0.02), WLZ (mean difference 0.001 SD, 95% CI -0.03 to 0.03), LAZ (mean difference -0.005 SD, 95% CI -0.03 to 0.02), or MUAC (mean difference 0.01 cm, 95% CI -0.01 to 0.04). The primary limitation of the trial was that measurements were only collected at enrollment and 6 months of age, precluding assessment of shorter-term or long-term changes in growth., Conclusions: Single-dose azithromycin does not appear to affect weight and height outcomes when administered during early infancy., Trial Registration: ClinicalTrials.gov NCT03676764., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Sié et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.